NASDAQ: TTOO (NASDAQ:TTOO) reported Q2 2018 earnings this Afternoon, coming in at ($0.32) per share, in-line Wall Street’s estimates of ($0.32) per Share. Revenue for the quarter came in at $3.90 million beating analyst estimates of $2.97 million Recent Insider Trading for NASDAQ: TTOO (NASDAQ:TTOO)
- On 6/5/2018 Stanley Lapidus, Director, sold 6,000 with an average share price of $8.87 per share and the total transaction amounting to $53,220.00.
- On 6/1/2018 David B Elsbree, Director, bought 4,225 with an average share price of $7.65 per share and the total transaction amounting to $32,321.25.
- On 11/16/2017 David B Elsbree, Director, bought 1,500 with an average share price of $4.11 per share and the total transaction amounting to $6,165.00.
- On 6/6/2017 Darlene M Deptula-Hicks, CFO, bought 4,000 with an average share price of $3.58 per share and the total transaction amounting to $14,320.00.
- On 6/6/2017 David B Elsbree, Director, bought 10,000 with an average share price of $3.50 per share and the total transaction amounting to $35,000.00.
- On 6/6/2017 Joanne Spadoro, COO, bought 5,000 with an average share price of $3.50 per share and the total transaction amounting to $17,500.00.
About Company T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.Recent Analyst Rating for NASDAQ: TTOO (NASDAQ:TTOO)
Recent Trading for NASDAQ: TTOO (NASDAQ:TTOO) Shares of NASDAQ: TTOO closed the previous trading session at 5.64 −0.030 0.53% with shares trading hands.